28 August 2026
Company IR: CTX310 durability heads to ESC and NEJM
On Aug. 28, 2026, CRISPR Therapeutics said Phase 1a CTX310 data showed 79% mean ANGPTL3 knockdown at the top dose at one year.
The full briefing is in the app.
28 August 2026
On Aug. 28, 2026, CRISPR Therapeutics said Phase 1a CTX310 data showed 79% mean ANGPTL3 knockdown at the top dose at one year.
The full briefing is in the app.